HK Stock Market Move | METIS TECHBIO-P (07666) has risen over 16%, accumulating a total increase of over 40% in three days, becoming the first strategic partner for AI drug delivery for LUYE PHARMA.

METIS TECHBIO-P (07666) rose by over 16% this morning, with its stock price accumulating a rise of over 40% in just three days. As of this report, it is up 13.38%, priced at HKD 19.92, with a trading volume of HKD 135 million. In terms of news, on September 8, Jitai Technology announced the official signing of a long-term strategic cooperation agreement with LUYE PHARMA Group in Beijing, making Jitai Technology the first strategic partner of LUYE PHARMA in the field of AI drug delivery. The two parties will engage in in-depth cooperation in four main areas, including the joint construction of an AI-driven R&D platform, collaboration on key technology breakthroughs, promotion of (results transformation), and the creation of an open innovation ecosystem. Professor Fu Fenghua, Executive Deputy Director of the National Key Laboratory of Advanced Drug Delivery Systems at LUYE PHARMA, stated, LUYE PHARMA has a deep foundation in long-acting controlled-release and targeted formulation fields, while Jitai Technology is a leader in the AI drug delivery sector. The strong alliance between the two will deeply embed AI throughout the drug delivery R&D chain, which is expected to significantly enhance the efficiency of innovative drug development and bring more clinically valuable innovative therapies to patients. Notably, starting from September 7, Jitai Technology officially entered the list of stocks eligible for Hong Kong Stock Connect. This means that mainland investors can now buy and sell Jitai Technology directly through the Shanghai and Shenzhen-Hong Kong Stock Connect, officially unlocking southbound capital. With the opening of the southbound capital channel, Jitai Technology is expected to gain higher market attention and continue to release platform value in the rapidly developing frontier of AI pharmaceuticals.